New targeted radiation treatment reduces bone pain, extends survival in prostate cancer patients

August 23, 2013

Prostate cancer that has spread to the bones can cause pain and fractures.

Loyola University Medical Center is among the first hospitals in Chicago to offer a new targeted that can reduce bone pain and the incidence of fractures – and also extend patients' lives.

The treatment, recently approved by the Food and Drug Administration, is called Xofigo®. A , radium-223, is injected into the patient. Because it is similar to calcium, radium-223 binds to the bone. Radium-223 delivers high- over a short distance, providing a targeted treatment that is less damaging to other structures or tissues, said Robert Wagner, MD, medical director of Nuclear Medicine in Loyola's Department of Radiology.

Radium-223 is rapidly cleared from the blood stream. Fifteen minutes after injection, about 20 percent of the injected radioactivity remains in the blood. By 24 hours, less than 1 percent of radioactivity remains.

Xofigo is indicated for prostate cancer patients in which:

- the cancer has spread to the bones, but not to other organs

- the cancer is not responding to hormone therapy or surgery that blocks production of testosterone, and

- the cancer spread to the bones is causing other serious symptoms.

Radium-223 is injected into an IV line in a patient's vein, in a procedure that takes less than 5 minutes. The patient receives a series of six injections, given once every four to six weeks.

Side effects can include upset stomach, diarrhea, swelling in the hands and feet and decreased counts of , and platelets.

"While the treatment is not a cure, it can enable patients to live longer, with significantly improved quality of life," Wagner said.

Explore further: Safer radium therapy provides hope for metastatic prostate cancer patients

Related Stories

Safer radium therapy provides hope for metastatic prostate cancer patients

July 18, 2013
A study of a new radiotherapeutic drug published this week in the New England Journal of Medicine brings fresh hope for a particular group of cancer patients that otherwise suffer and ultimately die from the disease—those ...

US approves radiation-based prostate cancer drug

May 15, 2013
(AP)—The U.S. Food and Drug Administration has approved a new injectable drug that uses radiation to treat advanced prostate cancer that has spread to the bones.

First Phase III trial of an alpha-pharmaceutical

September 23, 2011
Until recently, options for patients with bone metastases from advanced prostate cancer have been very limited. But now the first Phase III study of an alpha-pharmaceutical in these patients has shown that it can prolong ...

New therapy extends life for prostate cancer patients

June 11, 2012
Prostate cancer patients with advanced tumors that have spread to bone have a poor chance of surviving. Patients with the disease may now live longer with a new line of radioisotope therapy, say researchers at the Society ...

Therapy that heats and destroys bone tumors eases patients' pain

June 2, 2013
Patients with cancer that has spread to their bones are often treated with radiation therapy to reduce pain. But if that treatment doesn't work, or can't be used again, a second, effective option now exists. Results of a ...

Recommended for you

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.